Abstracts tagged "Systemic JIA"

Abstract Number: 2292 • 2014 ACR/ARHP Annual Meeting
Demographic, Clinical and Treatment Characteristics of the Childhood Arthritis and Rheumatology Research Alliance Registry Systemic JIA Cohort
Ginger L. Janow¹, Laura Schanberg², Soko Setoguchi³, Elizabeth D. Mellins⁴, Rayfel Schneider⁵, Yukiko Kimura^1,6 and The CARRA Registry Investigators⁷, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Duke University, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Dept of Pediatrics CCSR, Stanford University Medical Center, Stanford, CA, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁷Childhood Arthritis and Rheumatology Research Alliance, Durham, NC
Background/Purpose: Systemic JIA (sJIA) is a rare disease whose treatment has changed in the past 10 yrs. The Childhood Arthritis and Rheumatology Research Alliance (CARRA)…
Abstract Number: 2293 • 2014 ACR/ARHP Annual Meeting
Preliminary Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study
Yukiko Kimura¹, Esi Morgan-DeWitt², Kelly L. Mieszkalski³, Thomas Brent Graham⁴, Timothy Beukelman⁵, Maria F. Ibarra⁶, Norman T. Ilowite⁷, Marisa S. Klein-Gitelman⁸, Karen Onel⁹, Sampath Prahalad¹⁰, Marilynn G. Punaro¹¹, Sarah Ringold¹², Dana Toib¹³, Heather Van Mater¹⁴, Pamela F. Weiss¹⁵ and Laura Schanberg¹⁶, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Dept of Pediatrics, Duke University Medical Center, Durham, NC, ⁴Pediatric Rheumatology, Vanderbilt Children's Hospital, Nashville, TN, ⁵Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁷Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁸Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Division of Pediatric Rheumatology, University of Chicago, Chicago, IL, ¹⁰Emory University School of Medicine, Atlanta, GA, ¹¹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ¹²Seattle Children's Hospital, Seattle, WA, ¹³St. Christopher's Hospital for Children, Philadelphia, PA, ¹⁴Duke Pediatric Rheumatology, Duke University Medical Center, Hillsborough, NC, ¹⁵Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁶Duke University, Durham, NC
Background/Purpose: Treatment options for systemic JIA (sJIA) have recently expanded to include IL1 and IL6 inhibitors in addition to traditional treatments such as glucocorticoids (GC)…
Abstract Number: 2296 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Therapy in Children with Systemic Juvenile Idiopathic Arthritis. DATA from Russian Register of Sjia
Ekaterina Alexeeva^1,2, Saniya Valieva¹, Rina Denisova¹, Tatyana Bzarova¹, Kseniya Isayeva¹, Tatyana Sleptsova¹, Elena Mitenko¹, Evgeniya Chistyakova^1,2, Anna Fetisova¹ and Olga Lomakina³, ¹Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, ²I.M.Sechenov First Moscow State Medical University, Moscow, Russia, ³Scientific Center of Children's Health of RAMS, Moscow, Russia
Background/Purpose Systemic Juvenile Idiopathic Arthritis (sJIA) is classified as an acquired autoinflammatory disease. The interleukin-1 and interleukin-6 play a pivotal role in pathogenesis of this…
Abstract Number: 2297 • 2014 ACR/ARHP Annual Meeting
Efficacy of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) using JADAS Criteria – an Analysis of 12-Week Pooled Data
A. Ravelli¹, H. I. Brunner², N. Ruperto¹, P. Quartier³, A. Consolaro⁴, N.M. Wulffraat⁵, K. Lheritier⁶, C. Gaillez⁶, A. Martini¹ and D.J. Lovell², ¹PRINTO-Istituto Gaslini, Genova, Italy, ²PRCSG, Cincinnati, OH, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Pediatria II, PRINTO-Istituto Gaslini, Genova, Italy, ⁵UMC Utrecht, Utrecht, Netherlands, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose Chronic active disease and persistent synovial inflammation can lead to structural damage, joint destruction and impairment of physical function in patients with systemic juvenile…
Abstract Number: 2300 • 2014 ACR/ARHP Annual Meeting
Biologic Treatment in Systemic Juvenile Idiopathic Arthritis: Single Center Experience
Buthaina Al adba¹, Rayfel Schneider² and Earl Silverman³, ¹paediatric rheumatology, sickkids hospital, Toronto, ON, Canada, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Division of Rheumatology, Hosp for Sick Children, Toronto, ON, Canada
Background/Purpose: The prevalence of juvenile idiopathic arthritis (JIA) is approximately 3.3/1000 children and 10- 15% have the systemic form (SJIA). Biologics, specifically anti-IL -1 and…
Abstract Number: 1901 • 2014 ACR/ARHP Annual Meeting
Interferon-γ (IFNγ) in Macrophage Activation Syndrome (MAS) Associated with Systemic Juvenile Idiopathic Arthritis (sJIA). High Levels in Patients and a Role in a Murine MAS Model
Claudia Bracaglia¹, Ivan Caiello¹, Kathy De Graaf², Giovanni D'Ario², Florence Guilhot², Walter Ferlin², Lidia Meli¹, Giusi Prencipe¹, Sergio Davì³, Grant Schulert⁴, Angelo Ravelli⁵, Alexei Grom⁶, Cristina De Min² and Fabrizio De Benedetti Sr.¹, ¹Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ²Novimmmune S.A., Plan-Les-Ouates, Geneva, Switzerland, ³Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ⁴Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Istituto Giannina Gaslini and University of Genova, Genova, Italy, ⁶Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: IFNγ is the pivotal mediator in murine models of primary HLH. Given the similarities between primary and secondary (sHLH), including MAS, we analyzed IFNγ…
Abstract Number: 1900 • 2014 ACR/ARHP Annual Meeting
HLA-DRB1*1101, Regulatory Variants of the MHC, and a Regulatory Region Near an Intergenic Long Noncoding RNA on Chromosome 1 Are Risk Factors for Systemic Juvenile Idiopathic Arthritis
Michael J. Ombrello¹, Elaine F. Remmers², Ioanna Tachmazidou³, Alexei Grom⁴, Dirk Föll⁵, Alberto Martini⁶, Marco Gattorno⁷, Seza Ozen⁸, Sampath Prahalad^9,10, Andrew S. Zeft¹¹, John F. Bohnsack¹², Norman T. Ilowite¹³, Jane L. Park¹⁴, Elizabeth D. Mellins¹⁵, Ricardo A. G. Russo¹⁶, Claudio A. Len¹⁷, Sheila K. Feitosa de Oliveira¹⁸, Rae SM Yeung¹⁹, Lucy R. Wedderburn^20,21, Jordi Anton²², Tobias Schwarz²³, Buhm Han²⁴, Richard H. Duerr²⁵, Jean-Paul Achkar²⁶, M. Ilyas Kamboh²⁷, Kenneth M. Kaufman²⁸, Leah C. Kottyan²⁸, Dalila Pinto²⁹, Stephen Scherer³⁰, Marta E. Alarcón-Riquelme³¹, Elisa Docampo Martinez³², Xavier Estivill³³, Ahmet Gul³⁴, Colleen Satorius³⁵, Paul I.W. de Bakker^36,37,38, Soumya Raychaudhuri^37,39,40, Carl D. Langefeld⁴¹, Susan D. Thompson⁴², Eleftheria Zeggini³, Wendy Thomson⁴³, Daniel L. Kastner⁴⁴, Patricia Woo⁴⁵ and International Childhood Arthritis Genetics (INCHARGE) Consortium, ¹Translational Genetics and Genomics Unit, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³The Wellcome Trust Sanger Institute, Cambridge, United Kingdom, ⁴Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatric Rheumatology and Immunology, University Children's Hospital Muenster, Muenster, Germany, ⁶University of Genova, Genova, Italy, ⁷Pediatric Rheumatology, Instituto Giannina Gaslini, Genoa, Italy, ⁸Deptartment. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ⁹Emory University School of Medicine, Atlanta, GA, ¹⁰Children's Healthcare of Atlanta, Atlanta, GA, ¹¹Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ¹²Pediatriacs, University of Utah, Salt Lake City, UT, ¹³Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ¹⁴Pediatric Rheumatology, Stanford University Medical Center, Stanford, CA, ¹⁵Dept of Pediatrics CCSR, Stanford University Medical Center, Stanford, CA, ¹⁶Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, ¹⁷Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil, ¹⁸Pediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²⁰University College London (UCL) Institute of Child Health, London, United Kingdom, ²¹Great Ormond Street Hospital, London, United Kingdom, ²²Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, ²³Pediatric rheumathology and osteology, University of Wuerzburg, Wuerzburg, Germany, ²⁴Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, ²⁵Department of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA, ²⁶Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, ²⁷Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, ²⁸Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁹Genetics and Genomi Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, ³⁰The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON, Canada, ³¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³²Unit of Animal Genomics, GIGA-Université de Liège, LIege, Belgium, ³³Genetic Causes of Disease Laboratory, Center for Genomic Regulation, Barcelona, Spain, ³⁴Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³⁵National Human Genome Research Institute, Bethesda, MD, ³⁶Brighan and Women's Hospital, Harvard Medical School, Boston, MA, ³⁷Broad Institute of MIT and Harvard, Cambridge, MA, ³⁸University Medical Center Utrecht, Utrecht, Netherlands, ³⁹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁴⁰Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁴¹Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁴²Division and Center for Autoimmune Disease Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴³Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁴⁴Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ⁴⁵Paediatric Rheumatology Unit, University College London, London, United Kingdom
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe inflammatory disease of unknown etiology. We utilized a genomic approach to interrogate the molecular pathogenesis of…
Abstract Number: 931 • 2014 ACR/ARHP Annual Meeting
Response to Canakinumab Treatment Is Maintained in Systemic Juvenile Idiopathic Arthritis Patients
N.M. Wulffraat^1,2, N. Ruperto², H.I. Brunner³, S. Oliveira², Y. Uziel², K. Nistala², R. Cimaz², M. Ferrandiz², B. Flato², M.L. Gamir², I. Koné-Paut², C. Gaillez⁴, K. Lheritier⁴, K. Abrams⁵, A. Martini² and D.J. Lovell³, ¹Pediatric Rheumatology, UMC Utrecht, Utrecht, Netherlands, ²PRINTO-Istituto Gaslini, Genova, Italy, ³PRCSG, Cincinnati, OH, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Canakinumab, a selective, human, anti-interleukin (IL) -1β monoclonal antibody, is approved for the treatment of systemic juvenile idiopathic arthritis (SJIA) patients (≥ 2 years…
Abstract Number: 319 • 2014 ACR/ARHP Annual Meeting
Systemic Juvenile Idiopathic Arthritis and Exposure to Fine Particulate Air Pollution
Andrew S. Zeft¹, Sampath Prahalad², Rayfel Schneider³, Alexei Grom⁴, Fatma Dedeoglu⁵, Pamela F. Weiss⁶, Carter Mix⁷ and C. Arden Pope⁸, ¹Pediatrics, Rheumatology, The Cleveland Clinic, Cleveland, OH, ²Emory University, Atlanta, GA, ³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵on behalf of CARRAnet Investigators, Palo Alto, CA, ⁶Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ⁷Brigham Young University, Provo, UT, ⁸Economics, Brigham Young University, Provo, UT
Background/Purpose: Environmental factors are understood to play a pathogenic role in the etiology of Systemic Onset Juvenile Idiopathic Arthritis (SJIA). Fine particulate matter (aerodynamic diameter…
Abstract Number: 2790 • 2013 ACR/ARHP Annual Meeting
The Research In Arthritis In Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Are We Achieving Clinically Important Outcomes?
Deborah M. Levy¹, Shirley ML Tse¹, Elizabeth Stringer², Jaime Guzman³, Roberta A. Berard⁴, Karen Watanabe Duffy⁵, Dax Rumsey¹, Mercedes O. Chan³, Rosie Scuccimarri⁶, Adam M. Huber⁷, Lori B. Tucker³, Rae SM Yeung¹, Ciaran M. Duffy⁵, Kiem Oen⁸ and The ReACCh Out Investigators⁹, ¹Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, IWK Health Centre, Halifax, NS, Canada, ³Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁴Children's Hospital of Western Ontario, London, ON, Canada, ⁵Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Pediatrics, Children's Hospital of Winnipeg and University of Manitoba, Winnipeg, MB, Canada, ⁹The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Recent data suggests that achievement of inactive disease and early disease remission may result in improved outcomes for patients with juvenile idiopathic arthritis (JIA). …
Abstract Number: 2169 • 2013 ACR/ARHP Annual Meeting
Short Term Efficacy Of Biologic Agents In Patients With Systemic Juvenile Idiopathic Arthritis: Network Meta-Analysis Of Randomized Trials
Simon Tarp¹, Gil Amarilyo², Ivan Foeldvari³, Neta Cohen⁴, Tracy D. Pope⁵, Jennifer M.P. Woo⁶, Robin Christensen¹ and Daniel Furst⁵, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²Dana-Dwek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁴Dana-Duek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁵David Geffen School of Medicine, University of California, Los Angeles, CA, ⁶Pediatric Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe subtype of JIA, which includes systemic features such as fever, rash, elevated inflammatory markers along with…
Abstract Number: 1784 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of First Line Use Of Recombinant IL-1RA Treatment In Steroid naïve Systemic Juvenile Idiopathic Arthritis: Results Of a Prospective Cohort Study
S.J. Vastert¹, Wilco de Jager², Bo Jan Noordman², Dirk Holzinger³, Wietse Kuis⁴, Berent J. Prakken² and Nico M. Wulffraat⁵, ¹Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Institute of Immunology, University Muenster, Muenster, Germany, ⁴Pediatric immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵UMC Utrecht, Utrecht, Netherlands
Background/Purpose: To perform a prospective cohort study with recombinant IL-1RA (Anakinra, rIL-1RA) as first-line therapy in newly onset sJIA. Methods: Patients fulfilled the ILAR criteria…
Abstract Number: 269 • 2013 ACR/ARHP Annual Meeting
Marked Improvement In Patient Reported Outcomes Of Children With Active Systemic Juvenile Idiopathic Arthritis With Canakinumab Treatment – Results Of The Phase III Program
Rayfel Schneider¹, Hermine Brunner¹, Nicolino Ruperto², Nico Wulffraat², Pierre Quartier³, Riva Brik², Liza McCann², Helen E. Foster², Michael Frosch², Valeria Gerloni², Liora Harel², Claudio Len², Kristin Houghton¹, Rik Joos², Ken Abrams⁴, Karine Lheritier⁵, Sophia Kessabi⁵, Alberto Martini² and Daniel J. Lovell¹, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ²Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Efficacy and safety of canakinumab (CAN), a selective, fully human, anti-interleukin-1β monoclonal antibody, in systemic juvenile idiopathic arthritis (SJIA) patients has been demonstrated in…
Abstract Number: 271 • 2013 ACR/ARHP Annual Meeting
Baseline Characteristics Of Patients With Active Systemic JIA On Canakinumab Therapy Successfully Discontinuing Corticosteroids: Secondary Analyses From A Pivotal PHASE 3 Study
Hermine Brunner¹, Nicolino Ruperto², Tamás Constantin³, Nico Wulffraat^2,4, Gerd Horneff⁴, Jordi Anton², Reinhard Berner², Fabrizia Corona⁵, Rubén J. Cuttica⁶, Marine Desjonqueres², Michel Fischbach², Maria Alessio², Alice Chieng², Wolfgang Emminger², Elie Haddad⁷, Karine Lheritier⁸, Ken Abrams⁹, Josef Hruska⁸, Daniel J. Lovell⁷ and Alberto Martini², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ³Pediatric Rheumatology, University Childrens Hospital, Budapest, Hungary, ⁴PRINTO, Genoa, Italy, ⁵PRINTO-Istituto Gaslini, Genova, Italy, ⁶Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁷Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Interleukin-1β (IL-1β) is a key cytokine in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Canakinumab (CAN), a selective fully human anti-IL-1β monoclonal antibody,…
Abstract Number: 275 • 2013 ACR/ARHP Annual Meeting
Changes In Serum IL-18 Level In Systemic Juvenile Idiopathic Arthritis Patients Who Attained Drug-Free Remission By Tocilizumab
Tomohiro Kubota¹, Syuji Takei², Yuichi Yamasaki¹, Junko Yasumura³, Naomi Kuwada⁴, Yukiko Nonaka⁵, Tomoko Takezaki⁵, Tsuyoshi Yamatou⁵, Tomokazu Nagakura⁶, Yasuhito Nerome⁵, Hiroyuki Imanaka⁵ and Harumi Akaike⁵, ¹Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ²School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ³Dept of Pediatrics, Graduate School of Biomedical Sciences, Faculty of Medicine, Hiroshima University, Hiroshima City, Japan, ⁴Dept of Pediatrics, Faculuty of Medicine, Kumamoto University, Kumamoto City, Japan, ⁵Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ⁶Department of Pediatrics, House of Meguminoseibo, Usuki, Japan
Background/Purpose: Tocilizumab (TCZ), anti-human interleukin-6 receptor monoclonal antibody, was the first biologic agent used in the treatment of systemic juvenile idiopathic arthritis (sJIA) in Japan.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].